Memphasys Limited (ASX:MEM)

Market Cap	14.24M +34.0%
Revenue (ttm)	213.98K +52.1%
Net Income	-4.41M
EPS	-0.00
Shares Out	2.85B
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,206,410
Average Volume	2,075,097
Open	0.0050
Previous Close	0.0045
Day's Range	0.0050 - 0.0050
52-Week Range	0.0030 - 0.0110
Beta	0.37
RSI	44.94
Earnings Date	Mar 3, 2026

About Memphasys

Memphasys Limited develops, manufactures, and sells cell and protein separation devices, and related consumables for the healthcare, veterinary, and biotechnology market sectors in Australia. The company offers Felix system, a device separates sperm from raw semen by electrophoresis process and size exclusion membranes. It also provides RoXsta, a rapid in vitro antioxidant assessment; and AI-Port, an ambient temperature semen transport device for artificial insemination in animals. In addition, the company develops ambient temperature storage p...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2006
• Employees: 24
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: MEM

Financial Performance

In fiscal year 2025, Memphasys's revenue was 526,921, an increase of 237.77% compared to the previous year's 156,000. Losses were -5.04 million, -6.19% less than in 2024.